NEWS RELEASE

Defyrus Contracts DEF201 Pilot Manufacturing (cGMP) with McMaster University

Web Site Release **April 16, 2010**

Toronto - today Defyrus announced the signing of a multi-year, pilot manufacturing contract with the Robert Fritzhenry Vector Lab (RFVL) of McMaster University, Hamilton ON Canada. Under the terms of the contract, RFVL will manufacture both industrial and cGMP quality DEF201 and Defilovir™ in support of Defyrus' preclinical and clinical development programs. At the forefront of adenoviral-based vector design and manufacture since the 1980s, RFVL will develop Master Cell and Master Viral Banks for pilot scale production of DEF201 and Defilovir™ and for the transition to large scale commercial manufacturing.

"Local, cost-effective cGMP pilot manufacturing effectively addresses our requirements for near term drug evaluation and early sales for emergency use" said Jeffrey Turner, President & CEO, Defyrus Inc. "this McMaster University facility is state of the art"

"Supporting Canadian innovation in adenoviral-vectored medical countermeasure development is important for domestic and international efforts to manage infectious viral disease outbreaks" stated Dr. Jack Gauldie, Director of Institute for Molecular Medicine, McMaster University, "DEF201 and Defilovir™ have real potential to assist in these emergencies"

About Defyrus
Defyrus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom and Canada to develop broad spectrum anti-viral drugs and immunopotentiators to improve vaccine performance as medical countermeasures to viral threats of military and public health interest. www.defyrus.com

About RFVL @ McMaster
McMaster University has established the Robert E. Fitzhenry Vector Laboratory as the 1st Canadian laboratory that can produce clinical-grade adenoviral vectors under GMP conditions. The 3000-square foot manufacturing facility, located in the Institute for Molecular Medicine, includes five separate cell culture rooms, each containing a Class 100 biosafety cabinet. Two clean rooms are outfitted with bioBubble® softwall technology with supply air delivered via ducts to terminal HEPA filters. One clean room is dedicated to processing and purification of vectors, and the other for aseptic filling. This facility serves the immediate needs to expedite the transition of promising bench research to bedside treatment, and at the same time minimizes the cost associated with production of high quality, clinical-grade vectors.

# # # #

For further information:

Dr. Jeffrey D. Turner
President & CEO
Tel: (613) 674-1138
info@defyrus.com

Mr. Dana Rath
Chief Financial Officer
Tel: (514) 939-2531
info@defyrus.com